+ Health and Sciences +

The U.S. Food and Drug Administration (FDA) has brazenly betrayed the public's trust by approving the world's first genetically modified (GM) animal in direct defiance of science – a transgenic salmon branded "AquAdvantage" that has never been proven safe for human consumption or the natural environment. The New York Times (NYT) reports that AquAdvantage, a product of AquaBounty Technologies, has received official FDA approval after years of fierce lobbying by its manufacturer in favor of open approval. Despite repeated warnings from detractors that AquAdvantage poses serious threats to aquatic ecosystems and humans, the FDA has determined that this GM fish is completely safe for everything and everyone on the planet.  Many of the claims made about AquAdvantage by its manufacturer have been debunked, including the lie that this "Frankenfish" grows more quickly than natural salmon and is less prone to disease – both of which claims are patently false.

A study conducted by American Heart Association suggests that people speaking multiple languages have better recovery from stroke than those who speak one language. Study Highlights Bilingual patients were twice as likely as those who spoke one language to have normal cognitive function after a stroke. Bilingual patients performed better than single language patients on attention, information retrieval and organization. Embargoed until  3 p.m. CT/4 p.m. ET, Thursday, Nov. 19 2015 DALLAS, Texas, Nov. 19, 2015— Bilingual patients were twice as likely as those who spoke one language to have normal cognitive functions after a  stroke , in a study reported in the American Heart Association journal  Stroke. Previous research found bilingualism may delay the onset of Alzheimer’s disease. “People tend to think of Alzheimer’s as the only cause of dementia, but they need to know that stroke is also an important cause,” said Subhash Kaul, D.M., senior investigator and developer of